tirzepatide surmount 1 Time to weight plateau with tirzepatide treatment in the SURMOUNT‐1 and SURMOUNT‐4 clinical trials - Horn - 2025 - Clinical Obesity

Tirzepatide for the Maintenance of Body Weight Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT‐MAINTAIN - Horn - 2025 - Obesity

29.12

★★★★☆4.8 (126)

SURMOUNT-2: Tirzepatide confers about 15% weight loss in adults with obesity and diabetes

21.95

★★★★★4.9 (98)

In the SURMOUNT-4 trial, 82.5% of adults with obesity regained ≥25% of initial weight lost within one year of tirzepatide withdrawal; most showed reversal of cardiometabolic improvements. https://bit.ly/4rBMZgh

22.82

★★★★★5.0 (157)

A 3-year study of tirzepatide in participants with obesity and prediabetes showed substantial and sustained weight reduction and decreased risk of progression to diabetes with tirzepatide, as compared with placebo. Full SURMOUNT-1

20.66

★★★★★4.7 (84)

Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial

20.10

★★★★★4.9 (203)

Weight reduction with different doses of Tirzepatide in Surmount 1

24.50

★★★★★5.0 (176)

SURMOUNT-1: Tirzepatide Drastically Reduces Weight in Obese Patients

29.42

★★★★★4.8 (132)